SECURITIES AND EXCHANGE COMMISSION
                      Washington, D.C. 20549
                                
                                
                            FORM  8-K
                                
                          CURRENT  REPORT
                            PURSUANT  TO
  SECTION  13  OR  15(d)  OF  THE  SECURITIES  EXCHANGE  ACT  OF
                              1934
                                
                                
                        January 10, 1997
                         Date of Report
                             
                                
                                
             --------------------------------------
                                
                                
                                
                   OSTEX  INTERNATIONAL, INC.
      Exact Name of Registrant as Specified in Its Charter
                                
                                
                                
                                
     WASHINGTON              0-25250             91-1450247
      State of           Commission File        IRS Employer
    Incorporation            Number         Identification Number
                                
                                
                                
                2203 AIRPORT WAY SOUTH, SUITE 400
                   SEATTLE, WASHINGTON  98134
                          206-292-8082
    Address and Telephone Number of Principal Executive Offices
                                
                                
                                
             --------------------------------------
                                
                                
                                
                              [N/A]
    Former Name or Former Address, if Changed Since Last Report
                                
                                
             --------------------------------------

                                
ITEM 5.   OTHER EVENTS

    BOARD ACTION.   On January 10, 1997, the Board of Directors  (the
"Board   of   Directors")  of  Ostex  International,  Inc.   (the
"Company")  declared a dividend of one preferred  share  purchase
right (a "Right") for each outstanding share of common stock, par
value $.01 per share (the "Common Shares"), of the Company.   The
dividend  is payable on January 27, 1997 (the "Record  Date")  to
the shareholders of record on that date.  Each Right entitles the
registered  holder to purchase from the Company one one-hundredth
of  share  of Series A Junior Participating Preferred Stock,  par
value $.01 per share (the "Preferred Shares"), of the Company  at
a  price  of $38 per one one-hundredth of a Preferred Share  (the
"Purchase  Price"), subject to adjustment.  The  description  and
terms  of  the  Rights are set forth in a Rights  Agreement  (the
"Rights   Agreement")   between  the  Company   and   ChaseMellon
Shareholder  Services  L.L.C.,  as  Rights  Agent  (the   "Rights
Agent").

    Approximately  12,438,667 Common Shares were  outstanding  as  of
January  27, 1997  Each Common Share outstanding at the close  of
business  on January 27, 1997 will receive one Right.  The  Board
of  Directors  of  the Company has reserved sufficient  Preferred
Shares for issuance upon exercise of the Rights.

    ANTITAKEOVER EFFECTS.   The  Rights  have  certain  antitakeover
effects and will cause substantial dilution to a person or  group
that attempts to acquire the Company on terms not approved by the
Board of Directors.  The Rights should not affect any prospective
offeror  willing  to make an all-cash offer at a  full  and  fair
price,  or willing to negotiate with the Board of Directors,  nor
will  the  Rights  interfere with any merger  or  other  business
combination approved by the Board of Directors

    TRIGGERING EVENTS.   Until the earlier to occur of (i)  10  days
following  a  public  announcement that  a  person  or  group  of
affiliated  or  associated persons (an  "Acquiring  Person")  has
acquired  beneficial ownership of 20% or more of the  outstanding
Common  Shares, or (ii) 10 business days (or such later  date  as
may  be  determined by action of the Board of Directors prior  to
such time as any person or group of affiliated persons becomes an
Acquiring  Person) following the commencement of, or announcement
of  an  intention to make, a tender offer or exchange  offer  the
consummation of which would result in the beneficial ownership by
a person or group of 20% or more of the outstanding Common Shares
(the earlier of such dates being called the "Distribution Date"),
the  Rights will be evidenced, with respect to any of the  Common
Share  certificates outstanding as of the Record  Date,  by  such
Common  Share certificate with a copy of this Summary  of  Rights
attached thereto.

    ATTACHMENT TO COMMON STOCK.  The Rights Agreement provides  that,
until  the Distribution Date (or earlier redemption or expiration
of the Rights), the Rights will be transferred with and only with
the  Common  Shares.   Until the Distribution  Date  (or  earlier
redemption  or  expiration  of  the  Rights),  new  Common  Share
certificates  issued after the Record Date upon transfer  or  new
issuance  of  Common Shares will contain a notation incorporating
the  Rights Agreement by reference.  Until the Distribution  Date
(or   earlier  redemption  or  expiration  of  the  Rights),  the
surrender  for  transfer of any certificates  for  Common  Shares
outstanding as of the Record Date, even without such notation  or
a  copy  of  this Summary of Rights being attached thereto,  will
also  constitute the transfer of the Rights associated  with  the
Common  Shares  represented  by such  certificate.   As  soon  as
practicable    following   the   Distribution   Date,    separate
certificates evidencing the Rights ("Right Certificates") will be
mailed to holders of record of the Common Shares as of the  close
of  business  on  the Distribution Date, and such separate  Right
Certificates alone will evidence the Rights.



    EXERCISE OF RIGHTS.    Until a Right is exercised,  the  holder
thereof,  as  such, will have no rights as a shareholder  of  the
Company, including, without limitation, the right to vote  or  to
receive dividends.  Nonexercisable  until the Distribution  Date,
the Rights will expire on January 27, 2007 (the "Final Expiration
Date"),  unless the Final Expiration Date is extended  or  unless
the  Rights are earlier redeemed or exchanged by the Company,  in
each case, as described below.

    The Purchase Price payable, and the number of Preferred Shares or
other  securities  or  property issuable, upon  exercise  of  the
Rights  are  subject to adjustment from time to time  to  prevent
dilution  (i)  in  the  event  of  a  stock  dividend  on,  or  a
subdivision,  combination or reclassification of,  the  Preferred
Shares, (ii) upon the grant to holders of the Preferred Shares of
certain rights or warrants to subscribe for or purchase Preferred
Shares  at  a  price,  or securities convertible  into  Preferred
Shares with a conversion price, less than the then-current market
price of the Preferred Shares, or (iii) upon the distribution  to
holders  of the Preferred Shares of evidences of indebtedness  or
assets  (excluding regular periodic cash dividends  paid  out  of
earnings  or retained earnings or dividends payable in  Preferred
Shares)  or of subscription rights or warrants (other than  those
referred to above).

    The  number  of  outstanding Rights and the number  of  one  one-
hundredths  of a Preferred Share issuable upon exercise  of  each
Right  are  also subject to adjustment in the event  of  a  stock
split  of  the  Common Shares or a stock dividend on  the  Common
Shares  payable  in Common Shares or subdivisions, consolidations
or combinations of the Common Shares occurring, in any such case,
prior to the Distribution Date.

    TERMS OF PREFERRED SHARES.   Preferred Shares purchasable  upon
exercise  of  the Rights will not be redeemable.  Each  Preferred
Share  will  be  entitled  to  a minimum  preferential  quarterly
dividend  payment  of $1 per share, but will be  entitled  to  an
aggregate dividend of 100 times the dividend declared per  Common
Share.  In the event of liquidation, the holders of the Preferred
Shares  will  be  entitled to a minimum preferential  liquidation
payment  of $100 per share, but will be entitled to an  aggregate
payment  of  100 times the payment made per Common  Share.   Each
Preferred  Share  will have 100 votes, voting together  with  the
Common   Shares.    Finally,  in  the  event   of   any   merger,
consolidation  or  other transaction in which Common  Shares  are
exchanged, each Share will be entitled to receive 100  times  the
amount received per Common  Share.  These rights are protected by
customary antidilution provisions.

    Because   of  the  nature  of  the  Preferred  Shares'  dividend,
liquidation and voting rights, the value of the one one-hundredth
interest in a Preferred Share purchasable upon exercise  of  each
Right should approximate the value of one Common Share.

    If  the  Company  is  acquired  in a  merger  or  other  business
combination transaction or 50% or more of its consolidated assets
or  earning power are sold after a person or group has become  an
Acquiring  Person,  proper provision will be made  so  that  each
holder of a Right will thereafter have the right to receive, upon
the  exercise thereof at the then current exercise price  of  the
Right,  that  number of shares of common stock of  the  acquiring
company  that at the time of such transaction will have a  market
value  of  two  times the exercise price of the  Right.   If  any
person  or  group of affiliated or associated persons becomes  an
Acquiring  Person, proper provision shall be made  so  that  each
holder  of a Right, other than Rights beneficially owned  by  the
Acquiring Person (which will thereafter be void), will thereafter
have  the  right to receive upon exercise that number  of  Common
Shares  having a market value of two times the exercise price  of
the Right.

    With certain exceptions, no adjustment in the Purchase Price will
be required until cumulative adjustments require an adjustment of
at  least  1%  in  such Purchase Price.  No fractional  Preferred
Shares  will  be issued (other than fractions that  are  integral
multiples  of one one-hundredth of a Preferred Share, which  may,
at  the  election  of  the  Company, be evidenced  by  depositary
receipts),  and, in lieu thereof, an adjustment in cash  will  be
made  based  on the market price of the Preferred Shares  on  the
last trading day prior to the date of exercise.



    EXCHANGE OF RIGHTS.    At any time after any  person  or  group
becomes an Acquiring Person and prior to the acquisition by  such
person  or group of 50% or more of the outstanding Common Shares,
the Board of Directors may exchange the Rights (other than Rights
owned  by  such person or group that will have become  void),  in
whole  or  in part, at an exchange ratio of one Common Share,  or
one  one-hundredth  of a Preferred Share, per Right  (subject  to
adjustment).

    REDEMPTION OF RIGHTS.   At any time prior to the acquisition by a
person or group of affiliated or associated persons of beneficial
ownership  of 20% or more of the outstanding Common  Shares,  the
Board  of  Directors may redeem the Rights in whole, but  not  in
part,  at  a price of $.0001 per Right (the "Redemption  Price").
The  redemption of the Rights may be made effective at such  time
on  such basis with such conditions as the Board of Directors  in
its   sole  discretion  may  establish.   Immediately  upon   any
redemption  of the Rights, the right to exercise the Rights  will
terminate and the only right of the holders of Rights will be  to
receive the Redemption Price.

    AMENDMENT OF RIGHTS.   The terms of the Rights may be amended  by
the  Board of Directors without the consent of the holders of the
Rights,  including  an  amendment  to  lower  certain  thresholds
described  above to not less than the greater of (i) the  sum  of
 .001% and the largest percentage of the outstanding Common Shares
then  known to the Company to be beneficially owned by any person
or group of affiliated or associated persons and (ii) 10%, except
that,  from  and  after  such time as  any  person  or  group  of
affiliated or associated persons becomes an Acquiring Person,  no
such  amendment may adversely affect the interests of the holders
of  the  Rights.  The ability of the Board of Directors to  amend
the  terms  of the Rights is in addition to and in no way  limits
the discretion of the Board of Directors to redeem the Rights.

    RIGHTS AGREEMENT.   A copy of the Rights Agreement has been filed
with  the Securities and Exchange Commission as an Exhibit  to  a
Registration Statement on Form 8-A dated  January  24,  1997.   A
copy of the Rights Agreement is available free of charge from the
Company.  This summary description of the Rights does not purport
to  be complete and is qualified in its entirety by reference  to
the  Rights  Agreement,  which is hereby incorporated  herein  by
reference.



ITEM 7(c).   EXHIBITS

  Exhibit                  
  Number        Description
- -----------     ----------------------------------------------------------    
* 4.1           Rights Agreement dated as of January 21, 1997
                between Ostex International, Inc. and ChaseMellon
                Shareholder Services L.L.C..
            
99.1            Press release issued January 22, 1997


  *  Incorporated herein by reference to Exhibit 2.1 to Registrant's
Form 8-A filed January 24, 1997.




                            SIGNATURE


Pursuant  to the requirements of the Securities Exchange  Act  of
1934, the registrant has duly caused this report to be signed  on
its behalf by the undersigned hereunto duly authorized.


Dated the 22th day of January, 1997.


                                        OSTEX  INTERNATIONAL,  INC.


                                By     /S/ Robert M. Littauer
                                   ---------------------------------
                                        Robert M. Littauer
                                     Senior Vice President of
                                       Finance & Operations




                       INDEX  TO  EXHIBITS
                               TO
                            FORM  8-K
                                
                                

  Exhibit                  
  Number        Description
- -----------     ----------------------------------------------------------     
* 4.1           Rights Agreement dated as of January 21, 1997
                between Ostex International, Inc. and ChaseMellon
                Shareholder Services L.L.C..
            
99.1            Press release issued January 22, 1997



   * Incorporated herein by reference to Exhibit 2.1 to Registrant's
Form 8-A filed January 24, 1997.

                

                
                      EXHIBIT 99.1 TO FORM 8-K
[OSTEX  LOGO]


FINANCIAL CONTACT:                      COMPANY CONTACT:
Lillian Armstrong/Adam Aron             Robert Littauer
Lippert/Heilshorn & Associates          Ostex International, Inc.
415-433-3777                            206-689-0592
e-mail:lillian@lhai.com                 e-mail: littauer@nwlink.com


      OSTEX INTERNATIONAL, INC. ADOPTS SHAREHOLDER RIGHTS PLAN


    SEATTLE, JANUARY 22, 1997 -- Ostex International, Inc. (NASDAQ
NM: OSTX)  announced today that its Board of Directors has
adopted a Shareholder Rights Plan  in which preferred stock
purchase rights have been granted as a non-taxable dividend at
the rate of one Right for each share of Common Stock held of
record as of the close of business on January 27, 1997.  The
Rights will expire in January, 2007.

    The Rights Plan, which is similar to plans adopted by more than
1,800 publicly-traded companies, is designed to deter coercive or
unfair takeover tactics. The Company's adoption of the Plan is
intended to protect the rights of its stockholders and is not in
response to any acquisition proposal.  The Rights are not
intended to prevent a takeover of the Company and will not do so.
The Rights are designed to provide adequate time for the Board
and shareholders to evaluate the fairness of a proposal.  The
Rights deal with the very serious problem of another person or
company using abusive tactics to deprive the Board and
shareholders of any real opportunity to determine the destiny of
the Company.

    In implementing the Plan, the Board has declared a dividend of
one Right for each outstanding share of Ostex Common Stock.  Each
Right, upon becoming exercisable, would entitle the holder
thereof to purchase 1/100th of a share of a new series of
Preferred Stock.  One one-hundredth of a share of Preferred Stock
is intended to be approximately the economic equivalent of one
share of Common Stock.

    At the time of adoption of the Shareholder Rights Plan, the
Rights are neither exercisable nor traded separately from the
Common Stock. The Rights will be exercisable only if a person or
group in the future becomes the beneficial owner of 20% or more
of the Common Stock, or announces a tender or exchange offer



which would result in its ownership of 20% or more of the Common
Stock, without approval by the Company's Board of Directors.

    Ten days after a public announcement that a person has become the
beneficial owner of 20% or more of the Common Stock, each holder
of a Right, other than the acquiring person, would be entitled to
purchase shares of Common Shares of the Company
at one-half of the then-current price. If the Company is acquired
in a merger, or 50% or more of the Company's assets are sold in
one or more related transactions, each Right would entitle the
holder thereof to purchase common stock of the acquiring company
at half of the then-current market price of such common stock.

    At any time after a person or group of persons becomes the
beneficial owner of 20% or more of the Common Stock, the Board of
Directors may exchange one share of Common Stock for each Right,
other than Rights held by the acquiring person.  Additional
details regarding the Rights Plan will be outlined in a summary
to be mailed to all stockholders following the Record Date.

    Ostex   International,  Inc.  is  engaged   in   the   discovery,
development,  sales and marketing of diagnostics and therapeutics
for  diseases  of  the skeleton.  The Company believes  its  lead
product,     Osteomark -Regiatered    Trademark-,     incorporates
breakthrough   technology  in  the  area   of   bone   resorption
measurement.   Ostex  has  performed collaborative  relationships
with  a number of leading diagnostic and pharmaceutical companies
to aid in the commercialization of Osteomark.